Shire Prevails In Patent Trial Over Mylan's Generic Lialda
Law360, New York (January 27, 2017, 8:45 PM EST) -- Following a four-day bench trial held in September, a Florida federal judge concluded on Friday that Mylan Pharmaceuticals Inc.'s proposed generic version of Shire Development LLC's bowel disease drug Lialda infringes Shire's name-brand patent.
According to the opinion, Shire proved that Mylan’s abbreviated new drug application infringed literally on two claims of the Lialda patent and also established secondary liability on the theory of induced and contributory infringement.
“Mylan seeks to ‘piggyback’ on the FDA approval of Lialda with the same active ingredient and a drug dissolution profile covered by the asserted claims,” the judge wrote.
Shire, along with its partners...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!